Authors :
Dr. Vidhi Shah; Dr. Prriya Eshpuniyani; Dr. Sameer Pathan; Dr. Raman Deshpande
Volume/Issue :
Volume 7 - 2022, Issue 10 - October
Google Scholar :
https://bit.ly/3IIfn9N
Scribd :
https://bit.ly/3U67f99
DOI :
https://doi.org/10.5281/zenodo.7263813
Abstract :
- Ductal Carcinoma in Situ (DCIS) is defined as
the presence of cancerous cells in the breast duct or
lobule in the absence of a breach of the basement
membrane. [1,2] It is associated with less than a 4%
incidence of nodal metastases. We report the case of an
83-year-old woman who presented with a solitary left
axillary lump. On investigation, she was found to have a
left axillary nodal mass with an occult breast primary.
She underwent modified radical mastectomy with final
histopathology showing DCIS in the breast with invasive
ductal carcinoma in the axillary lymph node
(Immunohistochemistry: Estrogen receptor (ER) and
Progesterone Receptor (PR) negative/Her2 Receptorpositive). At the end of a year's follow-up after surgery,
the patient has finished 17 cycles of trastuzumab and is
still alive and disease-free.
- Ductal Carcinoma in Situ (DCIS) is defined as
the presence of cancerous cells in the breast duct or
lobule in the absence of a breach of the basement
membrane. [1,2] It is associated with less than a 4%
incidence of nodal metastases. We report the case of an
83-year-old woman who presented with a solitary left
axillary lump. On investigation, she was found to have a
left axillary nodal mass with an occult breast primary.
She underwent modified radical mastectomy with final
histopathology showing DCIS in the breast with invasive
ductal carcinoma in the axillary lymph node
(Immunohistochemistry: Estrogen receptor (ER) and
Progesterone Receptor (PR) negative/Her2 Receptorpositive). At the end of a year's follow-up after surgery,
the patient has finished 17 cycles of trastuzumab and is
still alive and disease-free.
